TCM
GNOM icon

Triumph Capital Management’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Triumph Capital Management’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.7K Hold
400
– – ﹤0.01% 903
2026
Q1 		$17.5K Hold
400
– – ﹤0.01% 938
2025
Q4 		$18.2K Buy
+400
New +$17.7K ﹤0.01% 893

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Triumph Capital Management's GNOM Position: Q2 2026 in Review

Triumph Capital Management held its Global X Genomics & Biotechnology ETF (GNOM) position steady in Q2 2026 at 400 shares worth $22.7K. The position accounts for ﹤0.01% of the portfolio, ranked #903.

Triumph Capital Management first reported a position in GNOM in Q4 2025 and has held it in 3 quarters since. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

  • Triumph Capital Management held 400 shares of Global X Genomics & Biotechnology ETF worth $22.7K as of Q2 2026.
  • Triumph Capital Management left its Global X Genomics & Biotechnology ETF share count unchanged in Q2 2026.
  • Global X Genomics & Biotechnology ETF made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #903 holding.
  • Triumph Capital Management first reported a position in Global X Genomics & Biotechnology ETF in Q4 2025 and has held it in 3 quarters since.
  • 48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.